|
||||||
|
 | Fusion Gene Summary |
| Fusion Gene ORF analysis |
| Fusion Genomic Features |
| Fusion Protein Features |
| Fusion Gene Sequence |
| Fusion Gene PPI analysis |
| Related Drugs |
| Related Diseases |
Fusion gene:MAPK8IP3-TELO2 (FusionGDB2 ID:51571) |
Fusion Gene Summary for MAPK8IP3-TELO2 |
 Fusion gene summary |
| Fusion gene information | Fusion gene name: MAPK8IP3-TELO2 | Fusion gene ID: 51571 | Hgene | Tgene | Gene symbol | MAPK8IP3 | TELO2 | Gene ID | 23162 | 9894 |
| Gene name | mitogen-activated protein kinase 8 interacting protein 3 | telomere maintenance 2 | |
| Synonyms | JIP-3|JIP3|JSAP1|NEDBA|SYD2|syd | CLK2|TEL2|YHFS | |
| Cytomap | 16p13.3 | 16p13.3 | |
| Type of gene | protein-coding | protein-coding | |
| Description | C-Jun-amino-terminal kinase-interacting protein 3C-jun-amino-terminal kinase interacting protein 3JNK MAP kinase scaffold protein 3JNK-interacting protein 3JNK/SAPK-associated protein-1JNK/stress-activated protein kinase-associated protein 1homolog | telomere length regulation protein TEL2 homologTEL2, telomere maintenance 2, homologprotein clk-2 homolog | |
| Modification date | 20200313 | 20200313 | |
| UniProtAcc | Q9UPT6 | TTI2 | |
| Ensembl transtripts involved in fusion gene | ENST00000250894, ENST00000356010, ENST00000568271, | ENST00000564507, ENST00000262319, | |
| Fusion gene scores | * DoF score | 8 X 8 X 4=256 | 2 X 2 X 2=8 |
| # samples | 8 | 2 | |
| ** MAII score | log2(8/256*10)=-1.67807190511264 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | log2(2/8*10)=1.32192809488736 | |
| Context | PubMed: MAPK8IP3 [Title/Abstract] AND TELO2 [Title/Abstract] AND fusion [Title/Abstract] | ||
| Most frequent breakpoint | MAPK8IP3(1813007)-TELO2(1551664), # samples:2 | ||
| Anticipated loss of major functional domain due to fusion event. | |||
| * DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
| Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
| Partner | Gene | GO ID | GO term | PubMed ID |
| Fusion gene breakpoints across MAPK8IP3 (5'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
 |
| Fusion gene breakpoints across TELO2 (3'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
 |
| Fusion gene information from two resources (ChiTars 5.0 and ChimerDB 4.0) * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| Source | Disease | Sample | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| ChimerDB4 | PRAD | TCGA-HC-8265-01A | MAPK8IP3 | chr16 | 1813007 | - | TELO2 | chr16 | 1551664 | + |
| ChimerDB4 | PRAD | TCGA-HC-8265-01A | MAPK8IP3 | chr16 | 1813007 | + | TELO2 | chr16 | 1551664 | + |
Top |
Fusion Gene ORF analysis for MAPK8IP3-TELO2 |
| Open reading frame (ORF) analsis of fusion genes based on Ensembl gene isoform structure. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| ORF | Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| 5CDS-intron | ENST00000250894 | ENST00000564507 | MAPK8IP3 | chr16 | 1813007 | + | TELO2 | chr16 | 1551664 | + |
| 5CDS-intron | ENST00000356010 | ENST00000564507 | MAPK8IP3 | chr16 | 1813007 | + | TELO2 | chr16 | 1551664 | + |
| In-frame | ENST00000250894 | ENST00000262319 | MAPK8IP3 | chr16 | 1813007 | + | TELO2 | chr16 | 1551664 | + |
| In-frame | ENST00000356010 | ENST00000262319 | MAPK8IP3 | chr16 | 1813007 | + | TELO2 | chr16 | 1551664 | + |
| intron-3CDS | ENST00000568271 | ENST00000262319 | MAPK8IP3 | chr16 | 1813007 | + | TELO2 | chr16 | 1551664 | + |
| intron-intron | ENST00000568271 | ENST00000564507 | MAPK8IP3 | chr16 | 1813007 | + | TELO2 | chr16 | 1551664 | + |
| ORFfinder result based on the fusion transcript sequence of in-frame fusion genes. |
| Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | Seq length (transcript) | BP loci (transcript) | Predicted start (transcript) | Predicted stop (transcript) | Seq length (amino acids) |
| ENST00000250894 | MAPK8IP3 | chr16 | 1813007 | + | ENST00000262319 | TELO2 | chr16 | 1551664 | + | 3726 | 2052 | 136 | 3204 | 1022 |
| ENST00000356010 | MAPK8IP3 | chr16 | 1813007 | + | ENST00000262319 | TELO2 | chr16 | 1551664 | + | 3698 | 2024 | 126 | 3176 | 1016 |
| DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated. |
| Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | No-coding score | Coding score |
| ENST00000250894 | ENST00000262319 | MAPK8IP3 | chr16 | 1813007 | + | TELO2 | chr16 | 1551664 | + | 0.006302638 | 0.99369735 |
| ENST00000356010 | ENST00000262319 | MAPK8IP3 | chr16 | 1813007 | + | TELO2 | chr16 | 1551664 | + | 0.011824832 | 0.98817515 |
Top |
Fusion Genomic Features for MAPK8IP3-TELO2 |
| FusionAI prediction of the potential fusion gene breakpoint based on the pre-mature RNA sequence context (+/- 5kb of individual partner genes, total 20kb length sequence). FusionAI is a fusion gene breakpoint classifier based on convolutional neural network by comparing the fusion positive and negative sequence context of ~ 20K fusion gene data. From here, we can have the relative potentency of the 20K genomic sequence how individual sequnce will be likely used as the gene fusion breakpoints. |
| Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | 1-p | p (fusion gene breakpoint) |
| Distribution of 44 human genomic features loci across 20kb length fusion breakpoint regions. We integrated a total of 44 different types of human genomic feature loci information across five big categories including virus integration sites, repeats, structural variants, chromatin states, and gene expression regulation. More details are in help page. |
 |
| Distribution of 44 human genomic features loci across 20kb length fusion breakpoint regions that are ovelapped with the top 1% feature importance score regions. More details are in help page. |
 |
Top |
Fusion Protein Features for MAPK8IP3-TELO2 |
| Four levels of functional features of fusion genes Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr16:1813007/chr16:1551664) - FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels. - How to search 1. Put your fusion gene symbol. 2. Press the tab key until there will be shown the breakpoint information filled. 4. Go down and press 'Search' tab twice. 4. Go down to have the hyperlink of the search result. 5. Click the hyperlink. 6. See the FGviewer result for your fusion gene. |
 |
| Main function of each fusion partner protein. (from UniProt) |
| Hgene | Tgene |
| MAPK8IP3 | TELO2 |
| FUNCTION: The JNK-interacting protein (JIP) group of scaffold proteins selectively mediates JNK signaling by aggregating specific components of the MAPK cascade to form a functional JNK signaling module (PubMed:12189133). May function as a regulator of vesicle transport, through interactions with the JNK-signaling components and motor proteins (By similarity). Promotes neuronal axon elongation in a kinesin- and JNK-dependent manner. Activates cofilin at axon tips via local activation of JNK, thereby regulating filopodial dynamics and enhancing axon elongation. Its binding to kinesin heavy chains (KHC), promotes kinesin-1 motility along microtubules and is essential for axon elongation and regeneration. Regulates cortical neuronal migration by mediating NTRK2/TRKB anterograde axonal transport during brain development (By similarity). Acts as an adapter that bridges the interaction between NTRK2/TRKB and KLC1 and drives NTRK2/TRKB axonal but not dendritic anterograde transport, which is essential for subsequent BDNF-triggered signaling and filopodia formation (PubMed:21775604). {ECO:0000250|UniProtKB:Q9ESN9, ECO:0000269|PubMed:12189133, ECO:0000269|PubMed:21775604}. | 508 |
| Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at * Minus value of BPloci means that the break pointn is located before the CDS. |
| - In-frame and retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
| Hgene | MAPK8IP3 | chr16:1813007 | chr16:1551664 | ENST00000250894 | + | 16 | 32 | 440_554 | 631 | 1337.0 | Coiled coil | Ontology_term=ECO:0000255 |
| Hgene | MAPK8IP3 | chr16:1813007 | chr16:1551664 | ENST00000250894 | + | 16 | 32 | 58_177 | 631 | 1337.0 | Coiled coil | Ontology_term=ECO:0000255 |
| Hgene | MAPK8IP3 | chr16:1813007 | chr16:1551664 | ENST00000250894 | + | 16 | 32 | 12_100 | 631 | 1337.0 | Domain | RH1 |
| Hgene | MAPK8IP3 | chr16:1813007 | chr16:1551664 | ENST00000250894 | + | 16 | 32 | 520_594 | 631 | 1337.0 | Domain | RH2 |
| Hgene | MAPK8IP3 | chr16:1813007 | chr16:1551664 | ENST00000250894 | + | 16 | 32 | 209_225 | 631 | 1337.0 | Region | JNK-binding domain (JBD)%3B essential for its function in axon elongation |
| Hgene | MAPK8IP3 | chr16:1813007 | chr16:1551664 | ENST00000250894 | + | 16 | 32 | 423_458 | 631 | 1337.0 | Region | Leucine zipper-like domain (LZ)%3B essential for its function in axon elongation |
| Hgene | MAPK8IP3 | chr16:1813007 | chr16:1551664 | ENST00000250894 | + | 16 | 32 | 50_80 | 631 | 1337.0 | Region | Kinesin-binding domain (KBD)%3B essential for its function in axon elongation |
| - In-frame and not-retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
Top |
Fusion Gene Sequence for MAPK8IP3-TELO2 |
| For in-frame fusion transcripts, we provide the fusion transcript sequences and fusion amino acid sequences. To have fusion amino acid sequence, we ran ORFfinder and chose the longest ORF among the all predicted ones. |
| >51571_51571_1_MAPK8IP3-TELO2_MAPK8IP3_chr16_1813007_ENST00000250894_TELO2_chr16_1551664_ENST00000262319_length(transcript)=3726nt_BP=2052nt AGTGACGGGCGCAGCCTCGGCAGCGGCGGCGGCGGAGCCCTGAGGCGACAGCAGCTGCGGGAGGCGACGGGCTGCGGCCTGCGGAACCTG AGGCAGCTGGGGAGGGCCGGGCGCGCCGGCCGGATAGCGAGCCGCGCTGGCGGCGGCGGTGGCCGCGATGATGGAGATCCAGATGGACGA GGGCGGCGGCGTGGTGGTGTACCAGGACGACTACTGCTCCGGCTCGGTGATGTCGGAGCGGGTGTCGGGCCTGGCGGGCTCCATCTACCG CGAGTTCGAGCGCCTCATCCACTGCTACGACGAGGAGGTGGTCAAGGAGCTCATGCCGCTGGTGGTGAACGTGCTGGAGAACCTAGACTC GGTGCTCAGCGAGAACCAGGAGCACGAGGTGGAGCTGGAGCTGCTGCGCGAGGACAACGAGCAGCTGCTCACCCAGTACGAGCGTGAGAA GGCGCTGCGCAGGCAGGCGGAGGAGAAATTCATTGAGTTTGAAGATGCTCTGGAACAAGAGAAGAAAGAGCTGCAAATCCAGGTGGAGCA CTACGAGTTCCAGACGCGCCAGCTGGAGCTGAAGGCCAAGAACTATGCCGATCAGATTTCCCGGTTGGAGGAGCGGGAGTCGGAGATGAA GAAGGAGTACAATGCCCTGCACCAGCGGCACACAGAGATGATACAGACCTACGTGGAGCACATTGAGAGGTCCAAGATGCAGCAGGTCGG AGGAAACAGCCAGACCGAGAGCAGCCTGCCGGGGCGGAGGAAGGAGCGCCCCACCTCCCTGAACGTGTTCCCCCTGGCTGACGGCACGGT ACGTGCACAGATCGGGGGCAAGCTCGTGCCTGCGGGGGACCACTGGCACCTGAGTGACCTCGGCCAGCTGCAGTCCAGCTCCAGCTACCA GTGTCCACAGGATGAAATGTCCGAGTCAGGCCAGTCCTCGGCGGCCGCCACACCCAGCACCACAGGCACCAAGTCCAACACGCCCACATC CTCCGTGCCCTCGGCCGCCGTCACACCCCTCAACGAGAGCCTGCAGCCCCTGGGGGACTATGGCGTGGGCTCCAAGAACAGCAAGCGTGC CCGGGAGAAGCGCGACAGCCGCAACATGGAAGTACAGGTCACCCAGGAGATGCGCAACGTCAGTATAGGCATGGGCAGCAGTGACGAGTG GTCTGATGTTCAAGACATTATTGACTCCACGCCAGAGCTGGACATGTGTCCAGAGACCCGCCTGGACCGCACAGGAAGCAGCCCAACCCA GGGCATCGTGAACAAAGCTTTCGGCATCAACACCGACTCCCTGTACCATGAGCTGTCGACGGCAGGGTCTGAGGTCATCGGGGATGTGGA CGAAGGGGCCGACCTCCTAGGGGAGTTCTCAGTGCGCGATGATTTCTTTGGAATGGGCAAAGAAGTGGGGAATCTGCTACTGGAAAACTC ACAGCTTCTGGAAACCAAAAACGCCTTGAATGTGGTGAAGAATGACCTGATTGCCAAGGTCGACCAGCTGTCCGGGGAGCAGGAGGTGCT GAGGGGCGAGTTGGAGGCTGCTAAGCAGGCCAAAGTCAAGCTGGAAAACCGTATCAAGGAGCTGGAAGAGGAACTGAAAAGAGTGAAGTC CGAGGCCATCATCGCCCGCCGTGAACCCAAAGAAGAGGCGGAGGATGTAAGCAGCTATCTCTGTACAGAATCGGACAAAATCCCCATGGC CCAGCGCCGCCGCTTCACGCGGGTGGAGATGGCCCGTGTGCTCATGGAGCGGAACCAGTACAAGGAGCGGCTGATGGAGCTGCAGGAGGC TGTGCGGTGGACTGAGATGATCAGAGCGTCCCGAGAGCACCCATCCGTCCAGGAGAAGAAGAAGTCGACCATCTGGCAGTTCTTCAGCCG CCTCTTCAGCTCTTCCTCCAGCCCCCCTCCGGCCAAGCGCCCCTATCCCTCGGTGAACATCCACTACAAGTCACCCACCACTGCCGGCTT CAGCCAGCGCCGCAACCATGCCATGTGCCCGATCTCGGCAGGCAGCCGGCCCCTGGAATTCTTCCCTGACGACACGTCCCTCGTTCCAGC CACGGCAGAGCCCCCTGCAGAGACCCCCGCAGAGATCGTGGATGGCGGCGTCCCCCAAGCACAGCTGGCGGGCTCTGACTCGGACCTGGA CAGCGATGATGAGTTTGTCCCCTACGACATGTCGGGGGACAGAGAGCTGAAGAGCAGCAAGGCTCCTGCCTACGTCCGGGACTGCGTGGA AGCCCTGACCACGTCTGAGGACATAGAGCGCTGGGAGGCAGCCCTGCGGGCCCTTGAGGGCCTGGTCTACAGGAGCCCCACAGCCACTCG GGAGGTGAGCGTGGAGCTGGCCAAGGTGCTTCTGCATCTGGAGGAGAAGACCTGTGTGGTGGGATTTGCAGGGCTGCGCCAGAGAGCCCT GGTGGCCGTCACGGTCACAGACCCGGCCCCGGTGGCCGACTATCTGACCTCACAGTTCTATGCCCTCAACTACAGCCTCCGGCAGCGCAT GGACATCCTGGATGTGCTGACTCTGGCTGCCCAGGAGCTGTCTAGGCCTGGGTGCCTCGGGAGGACTCCCCAACCTGGCTCCCCAAGTCC CAACACCCCGTGCCTGCCAGAGGCAGCCGTCTCTCAGCCTGGCAGTGCCGTGGCGTCTGACTGGCGGGTGGTGGTGGAGGAGCGGATCAG AAGCAAGACCCAGCGGCTCTCCAAGGGTGGCCCGAGGCAGGGCCCGGCAGGCAGCCCCAGCAGATTCAACTCCGTGGCCGGCCACTTCTT CTTCCCCCTCCTTCAGCGCTTTGACAGGCCTCTGGTGACCTTCGACCTCTTGGGAGAAGACCAGCTGGTTCTCGGAAGGCTGGCGCACAC CTTAGGGGCCCTGATGTGCCTGGCTGTTAACACCACGGTGGCTGTGGCCATGGGCAAGGCCCTGCTGGAATTCGTGTGGGCCCTTCGCTT CCACATCGATGCCTACGTGCGCCAGGGGCTGTTGTCGGCCGTCTCCTCCGTCCTGCTCAGCCTGCCTGCTGCGCGCCTGCTGGAGGACCT GATGGACGAGCTGCTGGAAGCCCGGTCCTGGCTGGCGGACGTGGCTGAGAAAGACCCGGACGAGGACTGCAGGACGCTGGCACTGAGGGC CCTGCTGCTTCTGCAGAGACTCAAGAACAGGCTCCTCCCACCCGCGTCTCCCTAGTCCCTGGAGGCCTCCCCAGGACCACCCTCGCCGAC AGCAAGGCAGGCGGCTGAGCAGCGGCCTGGAGCAGCAGAGCCAGGCTTTGTAGCGAGGCCAGGTCTTCGGCCGCATCCGGTACGGAGAGT GCAGATGCAGGAAGGCCCGGCCTGCCGCTATTTATAGTGCAGCCAGTCCGCTAAAAATACACTGGGCCTGGGCACTGCCCGCCGGGACAT GGCAGCCTGGACGTGGGGCTGGGGCTGTGGGCGCTGCTGGCGGGGTTGACTCTTCCAGTGAGGGCAGAACCAGGCTGGCAGGAGGGGAGG ACGGTGTACCTGCTGCTCAGAGCCCCCAAGGCTCTCCTCTGAGAGCCACCAAGCAGGACAGAGCAGCTCTTGTCCCAGGTCCCTCGGGCT GAGCGCCGTGTCACCAGGAGAATAGTGCTCACAGCCCAGGCAGGGTGTGTGGCTCCTGGATGGGCTCGTGGGGCGGGATGGGACAGGGCA >51571_51571_1_MAPK8IP3-TELO2_MAPK8IP3_chr16_1813007_ENST00000250894_TELO2_chr16_1551664_ENST00000262319_length(amino acids)=1022AA_BP=635 MAAAVAAMMEIQMDEGGGVVVYQDDYCSGSVMSERVSGLAGSIYREFERLIHCYDEEVVKELMPLVVNVLENLDSVLSENQEHEVELELL REDNEQLLTQYEREKALRRQAEEKFIEFEDALEQEKKELQIQVEHYEFQTRQLELKAKNYADQISRLEERESEMKKEYNALHQRHTEMIQ TYVEHIERSKMQQVGGNSQTESSLPGRRKERPTSLNVFPLADGTVRAQIGGKLVPAGDHWHLSDLGQLQSSSSYQCPQDEMSESGQSSAA ATPSTTGTKSNTPTSSVPSAAVTPLNESLQPLGDYGVGSKNSKRAREKRDSRNMEVQVTQEMRNVSIGMGSSDEWSDVQDIIDSTPELDM CPETRLDRTGSSPTQGIVNKAFGINTDSLYHELSTAGSEVIGDVDEGADLLGEFSVRDDFFGMGKEVGNLLLENSQLLETKNALNVVKND LIAKVDQLSGEQEVLRGELEAAKQAKVKLENRIKELEEELKRVKSEAIIARREPKEEAEDVSSYLCTESDKIPMAQRRRFTRVEMARVLM ERNQYKERLMELQEAVRWTEMIRASREHPSVQEKKKSTIWQFFSRLFSSSSSPPPAKRPYPSVNIHYKSPTTAGFSQRRNHAMCPISAGS RPLEFFPDDTSLVPATAEPPAETPAEIVDGGVPQAQLAGSDSDLDSDDEFVPYDMSGDRELKSSKAPAYVRDCVEALTTSEDIERWEAAL RALEGLVYRSPTATREVSVELAKVLLHLEEKTCVVGFAGLRQRALVAVTVTDPAPVADYLTSQFYALNYSLRQRMDILDVLTLAAQELSR PGCLGRTPQPGSPSPNTPCLPEAAVSQPGSAVASDWRVVVEERIRSKTQRLSKGGPRQGPAGSPSRFNSVAGHFFFPLLQRFDRPLVTFD LLGEDQLVLGRLAHTLGALMCLAVNTTVAVAMGKALLEFVWALRFHIDAYVRQGLLSAVSSVLLSLPAARLLEDLMDELLEARSWLADVA -------------------------------------------------------------- >51571_51571_2_MAPK8IP3-TELO2_MAPK8IP3_chr16_1813007_ENST00000356010_TELO2_chr16_1551664_ENST00000262319_length(transcript)=3698nt_BP=2024nt GCAGCCTCGGCAGCGGCGGCGGCGGAGCCCTGAGGCGACAGCAGCTGCGGGAGGCGACGGGCTGCGGCCTGCGGAACCTGAGGCAGCTGG GGAGGGCCGGGCGCGCCGGCCGGATAGCGAGCCGCGCTGGCGGCGGCGGTGGCCGCGATGATGGAGATCCAGATGGACGAGGGCGGCGGC GTGGTGGTGTACCAGGACGACTACTGCTCCGGCTCGGTGATGTCGGAGCGGGTGTCGGGCCTGGCGGGCTCCATCTACCGCGAGTTCGAG CGCCTCATCCACTGCTACGACGAGGAGGTGGTCAAGGAGCTCATGCCGCTGGTGGTGAACGTGCTGGAGAACCTAGACTCGGTGCTCAGC GAGAACCAGGAGCACGAGGTGGAGCTGGAGCTGCTGCGCGAGGACAACGAGCAGCTGCTCACCCAGTACGAGCGTGAGAAGGCGCTGCGC AGGCAGGCGGAGGAGAAATTCATTGAGTTTGAAGATGCTCTGGAACAAGAGAAGAAAGAGCTGCAAATCCAGGTGGAGCACTACGAGTTC CAGACGCGCCAGCTGGAGCTGAAGGCCAAGAACTATGCCGATCAGATTTCCCGGTTGGAGGAGCGGGAGTCGGAGATGAAGAAGGAGTAC AATGCCCTGCACCAGCGGCACACAGAGATGATACAGACCTACGTGGAGCACATTGAGAGGTCCAAGATGCAGCAGGTCGGAGGAAACAGC CAGACCGAGAGCAGCCTGCCGGGGCGGAGGAAGGAGCGCCCCACCTCCCTGAACGTGTTCCCCCTGGCTGACGGCACGGTACGTGCACAG ATCGGGGGCAAGCTCGTGCCTGCGGGGGACCACTGGCACCTGAGTGACCTCGGCCAGCTGCAGTCCAGCTCCAGCTACCAGTGTCCACAG GATGAAATGTCCGAGTCAGGCCAGTCCTCGGCGGCCGCCACACCCAGCACCACAGGCACCAAGTCCAACACGCCCACATCCTCCGTGCCC TCGGCCGCCGTCACACCCCTCAACGAGAGCCTGCAGCCCCTGGGGGACTATGGCGTGGGCTCCAAGAACAGCAAGCGTGCCCGGGAGAAG CGCGACAGCCGCAACATGGAAGTACAGGTCACCCAGGAGATGCGCAACGTCAGTATAGGCATGGGCAGCAGTGACGAGTGGTCTGATGTT CAAGACATTATTGACTCCACGCCAGAGCTGGACATGTGTCCAGAGACCCGCCTGGACCGCACAGGAAGCAGCCCAACCCAGGGCATCGTG AACAAAGCTTTCGGCATCAACACCGACTCCCTGTACCATGAGCTGTCGACGGCAGGGTCTGAGGTCATCGGGGATGTGGACGAAGGGGCC GACCTCCTAGGGGAGTTCTCAGGAATGGGCAAAGAAGTGGGGAATCTGCTACTGGAAAACTCACAGCTTCTGGAAACCAAAAACGCCTTG AATGTGGTGAAGAATGACCTGATTGCCAAGGTCGACCAGCTGTCCGGGGAGCAGGAGGTGCTGAGGGGCGAGTTGGAGGCTGCTAAGCAG GCCAAAGTCAAGCTGGAAAACCGTATCAAGGAGCTGGAAGAGGAACTGAAAAGAGTGAAGTCCGAGGCCATCATCGCCCGCCGTGAACCC AAAGAAGAGGCGGAGGATGTAAGCAGCTATCTCTGTACAGAATCGGACAAAATCCCCATGGCCCAGCGCCGCCGCTTCACGCGGGTGGAG ATGGCCCGTGTGCTCATGGAGCGGAACCAGTACAAGGAGCGGCTGATGGAGCTGCAGGAGGCTGTGCGGTGGACTGAGATGATCAGAGCG TCCCGAGAGCACCCATCCGTCCAGGAGAAGAAGAAGTCGACCATCTGGCAGTTCTTCAGCCGCCTCTTCAGCTCTTCCTCCAGCCCCCCT CCGGCCAAGCGCCCCTATCCCTCGGTGAACATCCACTACAAGTCACCCACCACTGCCGGCTTCAGCCAGCGCCGCAACCATGCCATGTGC CCGATCTCGGCAGGCAGCCGGCCCCTGGAATTCTTCCCTGACGACACGTCCCTCGTTCCAGCCACGGCAGAGCCCCCTGCAGAGACCCCC GCAGAGATCGTGGATGGCGGCGTCCCCCAAGCACAGCTGGCGGGCTCTGACTCGGACCTGGACAGCGATGATGAGTTTGTCCCCTACGAC ATGTCGGGGGACAGAGAGCTGAAGAGCAGCAAGGCTCCTGCCTACGTCCGGGACTGCGTGGAAGCCCTGACCACGTCTGAGGACATAGAG CGCTGGGAGGCAGCCCTGCGGGCCCTTGAGGGCCTGGTCTACAGGAGCCCCACAGCCACTCGGGAGGTGAGCGTGGAGCTGGCCAAGGTG CTTCTGCATCTGGAGGAGAAGACCTGTGTGGTGGGATTTGCAGGGCTGCGCCAGAGAGCCCTGGTGGCCGTCACGGTCACAGACCCGGCC CCGGTGGCCGACTATCTGACCTCACAGTTCTATGCCCTCAACTACAGCCTCCGGCAGCGCATGGACATCCTGGATGTGCTGACTCTGGCT GCCCAGGAGCTGTCTAGGCCTGGGTGCCTCGGGAGGACTCCCCAACCTGGCTCCCCAAGTCCCAACACCCCGTGCCTGCCAGAGGCAGCC GTCTCTCAGCCTGGCAGTGCCGTGGCGTCTGACTGGCGGGTGGTGGTGGAGGAGCGGATCAGAAGCAAGACCCAGCGGCTCTCCAAGGGT GGCCCGAGGCAGGGCCCGGCAGGCAGCCCCAGCAGATTCAACTCCGTGGCCGGCCACTTCTTCTTCCCCCTCCTTCAGCGCTTTGACAGG CCTCTGGTGACCTTCGACCTCTTGGGAGAAGACCAGCTGGTTCTCGGAAGGCTGGCGCACACCTTAGGGGCCCTGATGTGCCTGGCTGTT AACACCACGGTGGCTGTGGCCATGGGCAAGGCCCTGCTGGAATTCGTGTGGGCCCTTCGCTTCCACATCGATGCCTACGTGCGCCAGGGG CTGTTGTCGGCCGTCTCCTCCGTCCTGCTCAGCCTGCCTGCTGCGCGCCTGCTGGAGGACCTGATGGACGAGCTGCTGGAAGCCCGGTCC TGGCTGGCGGACGTGGCTGAGAAAGACCCGGACGAGGACTGCAGGACGCTGGCACTGAGGGCCCTGCTGCTTCTGCAGAGACTCAAGAAC AGGCTCCTCCCACCCGCGTCTCCCTAGTCCCTGGAGGCCTCCCCAGGACCACCCTCGCCGACAGCAAGGCAGGCGGCTGAGCAGCGGCCT GGAGCAGCAGAGCCAGGCTTTGTAGCGAGGCCAGGTCTTCGGCCGCATCCGGTACGGAGAGTGCAGATGCAGGAAGGCCCGGCCTGCCGC TATTTATAGTGCAGCCAGTCCGCTAAAAATACACTGGGCCTGGGCACTGCCCGCCGGGACATGGCAGCCTGGACGTGGGGCTGGGGCTGT GGGCGCTGCTGGCGGGGTTGACTCTTCCAGTGAGGGCAGAACCAGGCTGGCAGGAGGGGAGGACGGTGTACCTGCTGCTCAGAGCCCCCA AGGCTCTCCTCTGAGAGCCACCAAGCAGGACAGAGCAGCTCTTGTCCCAGGTCCCTCGGGCTGAGCGCCGTGTCACCAGGAGAATAGTGC TCACAGCCCAGGCAGGGTGTGTGGCTCCTGGATGGGCTCGTGGGGCGGGATGGGACAGGGCACGGGCTCTCAGAAAATAAACTGCTTTAT >51571_51571_2_MAPK8IP3-TELO2_MAPK8IP3_chr16_1813007_ENST00000356010_TELO2_chr16_1551664_ENST00000262319_length(amino acids)=1016AA_BP=629 MAAAVAAMMEIQMDEGGGVVVYQDDYCSGSVMSERVSGLAGSIYREFERLIHCYDEEVVKELMPLVVNVLENLDSVLSENQEHEVELELL REDNEQLLTQYEREKALRRQAEEKFIEFEDALEQEKKELQIQVEHYEFQTRQLELKAKNYADQISRLEERESEMKKEYNALHQRHTEMIQ TYVEHIERSKMQQVGGNSQTESSLPGRRKERPTSLNVFPLADGTVRAQIGGKLVPAGDHWHLSDLGQLQSSSSYQCPQDEMSESGQSSAA ATPSTTGTKSNTPTSSVPSAAVTPLNESLQPLGDYGVGSKNSKRAREKRDSRNMEVQVTQEMRNVSIGMGSSDEWSDVQDIIDSTPELDM CPETRLDRTGSSPTQGIVNKAFGINTDSLYHELSTAGSEVIGDVDEGADLLGEFSGMGKEVGNLLLENSQLLETKNALNVVKNDLIAKVD QLSGEQEVLRGELEAAKQAKVKLENRIKELEEELKRVKSEAIIARREPKEEAEDVSSYLCTESDKIPMAQRRRFTRVEMARVLMERNQYK ERLMELQEAVRWTEMIRASREHPSVQEKKKSTIWQFFSRLFSSSSSPPPAKRPYPSVNIHYKSPTTAGFSQRRNHAMCPISAGSRPLEFF PDDTSLVPATAEPPAETPAEIVDGGVPQAQLAGSDSDLDSDDEFVPYDMSGDRELKSSKAPAYVRDCVEALTTSEDIERWEAALRALEGL VYRSPTATREVSVELAKVLLHLEEKTCVVGFAGLRQRALVAVTVTDPAPVADYLTSQFYALNYSLRQRMDILDVLTLAAQELSRPGCLGR TPQPGSPSPNTPCLPEAAVSQPGSAVASDWRVVVEERIRSKTQRLSKGGPRQGPAGSPSRFNSVAGHFFFPLLQRFDRPLVTFDLLGEDQ LVLGRLAHTLGALMCLAVNTTVAVAMGKALLEFVWALRFHIDAYVRQGLLSAVSSVLLSLPAARLLEDLMDELLEARSWLADVAEKDPDE -------------------------------------------------------------- |
Top |
Fusion Gene PPI Analysis for MAPK8IP3-TELO2 |
| Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in |
| Protein-protein interactors with each fusion partner protein in wild-type (BIOGRID-3.4.160) |
| Hgene | Hgene's interactors | Tgene | Tgene's interactors |
| - Retained PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Still interaction with |
| Hgene | MAPK8IP3 | chr16:1813007 | chr16:1551664 | ENST00000250894 | + | 16 | 32 | 458_514 | 631.6666666666666 | 1337.0 | NTRK2 |
| - Lost PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
| - Retained PPIs, but lost function due to frame-shift fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
Top |
Related Drugs for MAPK8IP3-TELO2 |
| Drugs targeting genes involved in this fusion gene. (DrugBank Version 5.1.8 2021-05-08) |
| Partner | Gene | UniProtAcc | DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
Top |
Related Diseases for MAPK8IP3-TELO2 |
| Diseases associated with fusion partners. (DisGeNet 4.0) |
| Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
Copyright 2021-Present -The University of Texas Health Science Center at Houston (UTHealth)
Web File Viewing | Emergency Information |Campus Carry|Site Policies